This study sought to evaluate the incidence, predictive factors, and prognostic value of new-onset atrial fibrillation (NOAF) following transcatheter aortic valve implantation (TAVI).
Background
Very few data exist on the occurrence of NOAF following TAVI.
Methods
A total of 138 consecutive patients with no prior history of atrial fibrillation (AF) underwent TAVI with a balloonexpandable valve. Patients were on continuous electrocardiogram monitoring until hospital discharge, and NOAF was defined as any episode of AF lasting Ͼ30 s. All clinical, echocardiographic, procedural, and follow-up data were prospectively collected. At 30-day follow-up, NOAF was associated with a higher rate of stroke/systemic embolism (13.6% vs. 3.2%, p ϭ 0.021, p ϭ 0.047 after adjustment for baseline differences between groups), with no differences in mortality rate between groups (NOAF: 9.1%, no-NOAF: 6.4%, p ϭ 0.57). At a median follow-up of 12 months (interquartile range: 5 to 20 months), a total of 27 patients (19.6%) had died, with no differences between the NOAF (15.9%) and no-NOAF (21.3%) groups, p ϭ 0.58. The cumulative rate of stroke and stroke/systemic embolism at follow-up were 13.6% and 15.9%, respectively, in the NOAF group versus 3.2% in the no-NOAF group (p ϭ 0.039, adjusted p ϭ 0.037 for stroke; p ϭ 0.020, adjusted p ϭ 0.023 for stroke/systemic embolism).
Conclusions
NOAF occurred in about one-third of the patients with no prior history of AF undergoing TAVI and its incidence was increased in patients with larger LA size and those undergoing transapical TAVI. NOAF was associated with a higher rate of stroke/systemic embolism, but not a higher mortality, at 30 Transcatheter aortic valve implantation (TAVI) has become an alternative treatment for patients with severe symptomatic aortic stenosis considered to be at very high or prohibitive operative risk (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . New-onset atrial fibrillation (NOAF) is a well-known complication of cardiovascular interventions, and its occurrence has been associated with a higher rate of periprocedural cerebrovascular events and cardiac mortality (11, 12) . However, very few data exist on the occurrence of NOAF following TAVI, and no studies to date have evaluated the predictive factors of this complication during transcatheter valve procedures. The potential See page 189 role of NOAF in the occurrence of cardioembolic events following TAVI is also unknown. The occurrence of cerebrovascular events is probably the most worrisome complication associated with TAVI, with an incidence of about 4% (1-10), one of the highest ever reported in the field of interven-tional cardiology. Although about one-third of cerebrovascular events occur during the TAVI procedure, Ͼ50% of them occur several days after TAVI (1) , suggesting that mechanisms other than those directly related to the procedure may be involved. The objectives of this study were therefore to determine the incidence and predictive factors of NOAF in patients with no history of chronic/paroxysmal atrial fibrillation (AF) undergoing TAVI, and to evaluate the prognostic value of NOAF as a complication of TAVI, with special attention to cardioembolic events.
Methods
Study population and TAVI procedures. Between May 2007 and May 2011, a total of 195 consecutive patients with severe symptomatic aortic stenosis underwent TAVI with a balloon-expandable valve (Edwards SAPIEN, SAPIEN XT, Edwards Lifesciences, Irvine, California) at our institution. Of these, 57 patients with prior chronic or paroxysmal AF were excluded, leading to a final study population of 138 patients. Details about the TAVI procedure (transfemoral and transapical) have been extensively explained in previous studies (3) . Selection of transapical approach was based on the following criteria: small diameter of the iliofemoral arteries (Ͻ8, Ͻ7, Ͻ6.5, and Ͻ6 mm for the 24-, 22-, 19-, and 18-F sheaths, respectively), significant peripheral vascular disease, severe calcification or tortuosity of both iliofemoral arteries, severely calcified or porcelain aorta, and horizontal ascending aorta. Patients received full-dose heparin (100 U/kg, adjusted for an activated clothing time Ͼ250 s) during the procedure, and aspirin (80 mg/day) ϩ clopidogrel (75 mg/day) were administered following the procedure. All procedures were performed under a compassionate clinical program approved by Health Canada (Ottawa, Ontario, Canada), and all patients provided signed informed consent for the procedures. Clinical, echocardiographic, and procedural data were entered prospectively into a dedicated database. Left atrial size was defined as the anteroposterior diameter measured during systole in the parasternal long-axis view by M-mode echocardiography using the leading edge of the posterior aortic wall to the leading edge of the posterior atrial wall. All periprocedural complications were recorded and defined on the basis of the Valve Aortic Research Consortium criteria (13) . Cerebrovascular events were classified as transient ischemic attack (TIA) or stroke, which in turn was also categorized in accordance to the Modified Rankin Scale (MRS) as major stroke if MRS Ն2 at 30 days, or minor stroke if MRS Ͻ2 at 30 days (13) . All cerebrovascular events were evaluated by a neurologist and confirmed through neuroimaging techniques. Strokes were further classified as early/procedure, if a new neurological deficit was immediately apparent upon recovery from anesthesia or within 24 h of the procedure, and late/post-procedure, defined as those occurring Ͼ24 h after the intervention. Systemic embolism was defined as an abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms (e.g., trauma, atherosclerosis, or instrumentation). NOAF definition. Patients were on continuous electrocardiogram monitoring until hospital discharge, and NOAF was defined as any episode of AF lasting longer than 30 s (14, 15) . The timing and duration of the NOAF episode and the need for electrical or pharmacological cardioversion were recorded. The duration of the NOAF episode was classified as follows: Ͻ1 min, 1 min to 1 h, 1 to 12 h, 12 to 24 h, 24 to 48 h, or Ͼ48 h. NOAF was managed following the criteria of the latest reviewed guidelines of the American College of Cardiology/ American Heart Association (15). Anticoagulation was started, unless contraindicated, immediately after the diagnosis of NOAF and continued for at least 1 month. In case of short episodes (Ͻ12 h) of AF, the potential risks/benefits of anticoagulation were evaluated in each patient, and the decision was finally made by the physician responsible for the patient. In patients with an epidural catheter for pain relief after transapical TAVI, anticoagulation was delayed 24 h after the removal of the catheter following the criteria of the American Association of Regional Anesthesia and Pain Medicine (16) . Warfarin was used as anticoagulant therapy in all cases, with the objective of an international normalized ratio between 2 and 3. Intravenous heparin was administered until therapeutic anticoagulation levels were achieved. Follow-up. The clinical follow-up was carried out through clinical visits or telephone contact and was available in 100% of the study population. Cardiovascular events were defined following the Valve Aortic Research Consortium criteria (13 formed to discriminate power of the atrial size for the occurrence of NOAF. The maximum sum of sensitivity and specificity was used as the criterion to identify an optimal cutoff point in the ROC analysis. The association between NOAF and clinical outcomes (i.e., cardioembolic events and death) was analyzed with the use of univariate and multivariate logistic regression (30-day outcomes) or Cox proportional hazards (late outcomes) analyses. The multivariate models were adjusted for the baseline differences (p Ͻ 0.05 in the univariate analysis) between the NOAF and no-NOAF groups. The variables included in the models were prior coronary bypass grafting, severely calcified or porcelain aorta, left atrial size, and transapical approach. Late outcomes were also assessed by KaplanMeier estimates and compared using the log-rank test. The results were considered significant with p values Ͻ0.05. All analyses were conducted using the statistical package SAS version 9.2 (SAS Institute, Cary, North Carolina).
Results
The clinical, echocardiographic, and procedural characteristics of the study population are shown in Table 1 . Procedural success and 30-day mortality rates were 93.5% and 7.3%, respectively. Eight patients (5.8%) had a stroke following the procedure, all of which were ischemic in etiology as evidenced by neuroimaging techniques. One more patient without prior significant peripheral artery disease who underwent transapical TAVI suffered acute left lower limb ischemia 2 days after the procedure secondary to an infrapopliteal arterial obstruction as diagnosed by Doppler ultrasonography. The initial management with anticoagulation therapy resolved the arterial occlusion, and no further intervention was required, which corroborated its thrombotic nature. NOAF occurred in a total of 44 patients (31.9%) within 30 days following TAVI. The timing and duration of the episodes of NOAF are shown in Figures 1 and 2 , respectively. NOAF occurred at a median time of 48 h (IQR: 0 to 72 h) following TAVI. Up to 40% of the NOAF episodes occurred either during (n ϭ 16, 36.3%) or within the 24 h following the procedure (n ϭ 2, 4.6%). A total of 10 arrhythmic episodes (22.7%) resolved spontaneously, lasting Ͻ12 h in all cases, and 34 episodes (77.3%) required 
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Continued Values are mean Ϯ SD, n (%), or median (interquartile range). ACE ϭ angiotensin-converting enzyme; ARA2 ϭ angiotensin II receptor antagonist; BMI ϭ body mass index; COPD ϭ chronic obstructive pulmonary disease; eGFR ϭ estimated glomerular filtration rate; LVEDD ϭ left ventricular end-diastolic diameter; LVEF ϭ left ventricular ejection fraction; NYHA ϭ New York Heart Association; PCI ϭ percutaneous coronary intervention; STS-PROM ϭ Society of Thoracic Surgeons predicted risk of mortality. pharmacological (intravenous amiodarone; n ϭ 19, 43.2%) or electrical (n ϭ 15, 34.1%) cardioversion. The cardioversion was effective in all but 1 patient, who remained in AF at hospital discharge. Anticoagulation (with intravenous heparin and warfarin) was initiated immediately after the diagnosis of NOAF in 34 of the 44 patients (77.3%) with NOAF. Anticoagulation treatment was delayed 24 h in 3 patients with epidural catheters to allow the safe removal of the catheter. In the other 7 patients, a decision to maintain antithrombotic treatment with aspirin and clopidogrel without anticoagulation was made due to the very short duration of the NOAF episode (Ͻ12 h in all of them) and an estimated high risk of bleeding with the addition of anticoagulation therapy. The length of hospital stay for the patients who experienced NOAF was 9 days (IQR: 7 to 14 days), which was significantly longer than that of the rest of the study population (6 days, IQR: 5 to 9 days, p ϭ0.0004). At hospital discharge, the antithrombotic treatment for the 44 patients who presented with NOAF was as follows: aspirin alone (n ϭ 2, 4.5%), aspirin ϩ clopidogrel (n ϭ 6, 13.6%), warfarin alone (n ϭ 1, 2.3%), warfarin ϩ aspirin (n ϭ 24, 54.5%), and warfarin ϩ aspirin ϩ clopidogrel (11 patients, 25.0%). A total of 14 patients (31.8%) and 20 patients (45.5%) were on amiodarone or beta-blockers, respectively, at hospital discharge. Mean international normalized ratio level at hospital discharge was 2.6 Ϯ 0.5 for the 36 patients under warfarin therapy, with 3 and 6 patients exhibiting international normalized ratio levels below 2 and above 3, respectively. Predictive factors of NOAF. Baseline and procedural characteristics of the patients grouped according to the occurrence of NOAF are shown in (Fig. 3) . The incidence of NOAF in patients with an atrial size Ն27 mm/m 2 undergoing TAVI by transapical approach was 51% compared with 12% in patients with an atrial size Ͻ27 mm/m 2 undergoing TAVI by transfemoral approach. Follow-up. The median follow-up for the study population was 12 months (IQR: 5 to 20 months). During the follow-up period, a total of 7 patients with NOAF (15.9%) had at least 1 more episode of AF compared with 2 patients (2.1%) in the group with no-NOAF at 30 days (p ϭ 0.005). The Kaplan-Meier curves at 1-year follow-up showing freedom from new episodes of AF during the follow-up period are shown in Figure 4 . A total of 17 patients (12.3%) died during the follow-up period: 4 (2.9%) from cardiac causes and 13 (9.4%) from noncardiac causes. Cerebrovascular events, systemic embolism, and NOAF. The incidence of cerebrovascular events, systemic embolism, and death following TAVI grouped according to the occurrence of NOAF are shown in Table 3 . The incidence of stroke at 30 days tended to be higher in the NOAF group (11.4%) compared with the no-NOAF group (3.2%, OR: 3.89, 95% CI: 0.89 to 17.08, p ϭ 0.056, p ϭ 0.068 after adjusting for baseline differences between groups), and the incidence of the combined endpoint of stroke and systemic embolism was higher in the NOAF group compared with the no-NOAF group (13.6% vs. 3.2%, OR: 4.79, 95% CI: 1.14 to 20.15, p ϭ 0.021, p ϭ 0.047 after adjusting for baseline differences between groups). During the follow-up period, 1 patient in the NOAF group had a stroke, and 1 patient in the no-NOAF group presented with a TIA, 22 and 4 months after the procedure, respectively. The cumulative incidence of stroke at follow-up was higher in the NOAF group compared with the no-NOAF group (13.6% vs. 3.2%, hazard ratio [HR]: 4.32, 95% CI: 1.08 to 17.28, p ϭ 0.039, p ϭ 0.037 after adjusting for baseline differences 
Figure 2 Duration of NOAF Episodes
Duration of the episodes of atrial fibrillation following TAVI. NOAF ϭ new-onset atrial fibrillation. 19.35; p ϭ 0.020, p ϭ 0.023 after adjusting for baseline differences between groups). The main individual characteristics and the timing of the event in the 9 patients who had a stroke and the patient who developed a systemic embolism following the procedure are shown in Table 4 . A total of 4 strokes occurred early (Յ24 h post-TAVI) and 5 late (Ͼ24 h post-TAVI). One of the 4 early strokes (25%) occurred in a patient with NOAF, whereas all 5 late strokes occurred in patients with NOAF (100%, p ϭ 0.048 compared with early strokes). Among the patients with NOAF, the stroke/systemic embolism rate at 30 days in those patients for whom anticoagulant therapy was not initiated immediately after the diagnosis of NOAF was 40% compared with 2.9% in those who received anticoagulant treatment immediately after the diagnosis of NOAF (p ϭ 0.008). Figure 5 shows the distribution of NOAF patients according to the duration of the NOAF episode, anticoagulant treatment upon the diagnosis of NOAF, and cardioembolic events. There were no differences between the NOAF and no-NOAF groups regarding follow-up mortality (NOAF: 15.9%, no-NOAF: 21.3%, HR: 0.79, 95% CI: 0.33 to 1.86, p ϭ 0.58, p ϭ 0.56 after adjusting for baseline differences) and the combined endpoint of death and stroke (NOAF: 27.3%, no-NOAF: 24.5%, HR: 1.16, 95% CI: 0.58 to 2.35, p ϭ 0.67, p ϭ 0.76 after adjusting for baseline differences). The Kaplan-Meier curves at 1-year follow-up for freedom of death, stroke, cerebrovascular event (stroke and TIA), and the combined endpoint of death and stroke are shown in Figure 6 . Discussion NOAF occurred in up to 31% of the patients with no prior chronic/paroxysmal AF undergoing TAVI with a balloonexpandable valve by transfemoral or transapical approach. A larger atrial size and transapical approach were the predictive factors of NOAF following TAVI. NOAF was associated with a higher rate of stroke or systemic embolism acutely and at midterm follow-up, but there were no differences in global and cardiac mortality between patients with and without NOAF.
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Very few data exist on the occurrence of NOAF following TAVI. In fact, NOAF has not been included as a potential complication of TAVI in any of the recent large multicenter TAVI registries (3) (4) (5) (6) (7) (8) (9) (10) . The PARTNER (Placement of Aortic Transcatheter Valve) trial (high-risk cohort) included 347 patients who underwent TAVI with a balloonexpandable valve either by transfemoral or transapical approach (2). The incidence of NOAF within 30 days was 15% among the patients with no prior AF, which is about one-half the incidence reported in the present study. Unlike our study, most (two-thirds) of the patients included in the Values are n (%) or median (25th to 75th interquartile range). *Values are expressed as odds ratios (OR) for 30-day outcomes and hazard ratios (HR) for follow-up (Ͼ30-day) outcomes and cumulative outcomes. †p Value refers to the significance of the logistic regression analysis (OR) or Cox proportional hazards regression (HR). CI ϭ confidence interval; NOAF ϭ new-onset atrial fibrillation; TIA ϭ transient ischemic attack.
PARTNER trial underwent the procedure by transfemoral approach, and the rate of NOAF was close to the rate of 16% observed in our cohort of transfemoral approach patients. Our patients also were continuously monitored until hospital discharge, and NOAF was defined as any episode of AF lasting Ͼ30 s (including those episodes during the TAVI procedure), with up to 5% of the AF episodes lasting Ͻ1 min and about one-third of them lasting Ͻ1 h. It is unclear whether prior studies were reporting such very short episodes of atrial arrhythmias, and this might explain the higher NOAF rate observed in our study. However, the 31% rate of NOAF observed in our study population would have decreased to 21% if patients with prior AF had not been excluded, and this incidence is still lower than the 33% to 49% rate reported following valvular cardiac surgery or the 36% to 63% rate reported following combined valvular and coronary artery bypass surgery (11) . To the best of our knowledge, this is the first study evaluating the timing and duration of NOAF following TAVI. Interestingly, about one-third of the AF episodes occurred during the TAVI procedure, and up to 45% of them occurred within the 24 h following TAVI. Also, and in accordance with previous cardiac surgery studies (11) , the occurrence of NOAF was associated with a prolongation of hospital stay (mean of 3 days), which in turn would be associated with a significant increase in hospital costs for the TAVI procedure. Predictive factors of NOAF following TAVI. Previous studies have shown an association between severe aortic stenosis and atrial enlargement (17, 18) , but no prior data were available for the subset of patients considered at very high or prohibitive surgical risk. The mean atrial size in our study population was larger than that observed in other studies in the general population and in patients with systemic hypertension (19, 20) . Aortic stenosis is associated with diastolic dysfunction, which in turn might lead to a dilation of the left atrium (17, 18, 21) . This atrial enlargement has been recognized as a predictive factor of NOAF following cardiac surgery as well as of AF recurrence in patients with paroxysmal AF (22, 23) . Atrial dilation is associated with fibrotic changes of the atrial wall and slow atrial conduction, which might increase the vulnerability for AF (24) . The present study has shown that atrial enlargement is an independent predictor of NOAF in patients undergoing TAVI, with an indexed atrial size of 27 mm/m 2 exhibiting the best sensitivity and specificity for predicting the occurrence of NOAF. The transapical approach was also an independent predictor of NOAF following TAVI. Unlike the transfemoral approach, the transapical approach requires a left mini-thoracotomy and a direct puncture of the left ventricular apex. It is well known from thoracic surgery studies (excluding cardiac interventions) that thoracotomy is associated with NOAF in 10% to 20% of patients (25, 26) . The ventilatory restriction and the hyperadrenergic status generated by post-operative pain have been identified as factors associated with NOAF following noncardiac thoracic interventions (25, 26) . Particularly in the transapical Amat-Santos et al. January 10, 2012:178-88 TAVI and Atrial Fibrillation approach, direct myocardial injury secondary to the apex puncture and surgical repair may also play a role in the occurrence of NOAF (27) . Several preventive strategies such us amiodarone, beta-blockers, or angiotensinconverting enzyme inhibitors/angiotensin II receptor antagonists have shown their efficacy in preventing NOAF in systemic hypertension following cardiac surgery procedures (21, 28) . Knowing the predictive factors of NOAF following TAVI should allow us to select the patients at higher risk for NOAF preventive studies in the setting of TAVI. NOAF and cardioembolic events following TAVI. The occurrence of cerebrovascular events has become the most worrisome complication associated with TAVI. The stroke rate of 5.8% at 30 days observed in the present study is consistent with the ϳ4% (0.6% to 5%) rate reported in recent multicenter registries (3-10) as well as with the 6.7% and 4.7% rates reported in the nonoperable and high-risk cohorts of the PARTNER trial, respectively (1,2). Transcranial Doppler studies have shown that cerebral emboli can occur any time during the TAVI procedure but seem to occur most frequently during valve prosthesis positioning and implantation, suggesting that the embolization of calcific particles from the native valve might be 1 of the main mechanisms for cerebrovascular events during TAVI procedures (29) . Consistent with the results of the present study, however, it has been shown that only about one-half of the neurological events are directly related to the TAVI procedure, whereas the other half are late (Ն24 h) events (1). Our results suggest that NOAF may be an important mechanism for the late neurological events after TAVI. All patients with a late (Ͼ24 h) stroke following TAVI had at least 1 episode of AF, compared with only 25% of the patients who complicated with a procedural stroke. Indeed, a plausible temporal relationship between NOAF and stroke was found in 4 of the 5 patients with late stroke and also in the patient who suffered a systemic embolism. Importantly, anticoagulation treatment was not optimal in 3 of the 5 patients with late stroke, either because the episode of AF was considered too short to start anticoagulant therapy (2 patients) or for safety reasons due to the presence of an epidural catheter for pain relief after a transapical procedure (1 patient). The risk of a cardioembolic event was as high as 40% in those patients who had NOAF and did not receive anticoagulant therapy, even if AF episodes were of short (Ͻ12 h) duration. These results strongly suggest that anticoagulation therapy should have been started immediately after diagnosis of the AF episode and continued for several months. No clear guidelines exist on anticoagulation therapy following short episodes of postoperative AF (15, 30) . However, patients undergoing TAVI nowadays are at high risk for thromboembolism in case of atrial arrhythmia (median CHADS2 score of the study population of 3), and a more aggressive antithrombotic treatment should probably be implemented in these cases. Also, although the guidelines recommend a 24-h delay for initiating anticoagulation in the presence of an epidural catheter (16), some recent studies have shown the safety of anticoagulant therapy in the presence of or when removing an epidural catheter (31, 32) . Finally, although double antiplatelet therapy with aspirin and clopidogrel has been empirically recommended following TAVI, future randomized studies will have to evaluate the more appropriate antithrombotic treatment following these procedures and the potential role for systematic anticoagulant therapy either with warfarin or direct thrombin inhibitors in this setting. Study limitations. Although patients with known chronic or paroxysmal AF were excluded from this study, and all patients were in sinus rhythm at baseline, no electrocardiogram monitoring studies were performed before the TAVI procedures to evaluate the presence of silent episodes of AF. Although the occurrence of NOAF remained associated with a higher rate of cardioembolic events after adjustment for baseline differences between groups (NOAF vs. no-NOAF), the total number of events was relatively low, and this may have led to overfitting of the multivariate model. These results must, therefore, be confirmed by larger studies.
Conclusions
NOAF is a frequent complication associated with TAVI, with about half of the AF episodes occurring within 24 h and Ͼ80% within the first 3 days after the procedure. Larger atrial size and transapical approach were independent predictors of NOAF following TAVI. The mortality rates at 30 days and at follow-up were similar between patients with and without NOAF. However, NOAF was associated with a higher rate of cardioembolic events (stroke, systemic embolism) following the procedure, especially late (Ͼ24 h) events, and this provides important new insight into the mechanisms of cerebrovascular events following TAVI. Indeed, some cardioembolic events seemed to be related to the no initiation of anticoagulant therapy upon documentation of the AF episode, which further emphasizes the clinical relevance of optimizing antithrombotic treatment in this high-risk subset of patients. It is also important to note that these results were obtained in a TAVI cohort made up predominantly of patients treated by transapical approach. Finally, future studies will have to determine the potential usefulness of implementing preventive strategies to reduce the occurrence of NOAF and its potentially devastating consequences in the setting of TAVI.
